for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Audentes Therapeutics Inc

BOLD.OQ

Latest Trade

59.44USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

18.00

 - 

59.62

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
59.44
Open
--
Volume
--
3M AVG Volume
22.48
Today's High
--
Today's Low
--
52 Week High
59.62
52 Week Low
18.00
Shares Out (MIL)
45.78
Market Cap (MIL)
2,721.36
Forward P/E
-14.27
Dividend (Yield %)
--

Latest Developments

More

Audentes Therapeutics Reports Q3 Loss Per Share Of $1.00

Audentes Therapeutics Presents New Positive Data From Aspiro

Audentes Therapeutics Posts Q2 Loss Per Share Of $1.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Audentes Therapeutics Inc

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Industry

Biotechnology & Drugs

Contact Info

600 California St Fl 17

+1.415.6386556

https://www.audentestx.com/

Executive Leadership

Matthew R. Patterson

Chairman of the Board, Chief Executive Officer

Natalie C. Holles

President, Chief Operating Officer

Thomas J. Schuetz

Co-Founder, Independent Director

Thomas P. Soloway

Chief Financial Officer, Executive Vice President

Mark A. Meltz

Senior Vice President, General Counsel

Key Stats

2.93 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-5.590

2017

-3.400

2018

-3.400

2019(E)

-4.165
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-47.94
Return on Equity (TTM)
-45.04

Latest News

Latest News

Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet

Japan's Astellas Pharma Inc <4503.T> is buying U.S. drugmaker Audentes Therapeutics Inc <BOLD.O> for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.

CORRECTED-Japan's Astellas Pharma to buy Audentes Therapeutics for $2.7 bln

Japan's Astellas Pharma Inc said on Monday it had agreed to buy Audentes Therapeutics Inc for $2.7 billion in cash as it looks to bolster its position in the gene therapy market.

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

BRIEF-Audentes Therapeutics Reports Qtrly Loss Per Share $0.74

* AUDENTES THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Audentes Therapeutics CEO Matthew Patterson's 2017 Total Compensation Was $6.9 Million

* AUDENTES THERAPEUTICS INC SAYS CEO MATTHEW PATTERSON'S 2017 TOTAL COMPENSATION WAS $6.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KknZ9F) Further company coverage:

BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82

* AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Wellington Management Group Llp Reports 10.85 pct Passive Stake In Audentes Therapeutics As Of Jan 31, 2018

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 10.85 PERCENT PASSIVE STAKE IN AUDENTES THERAPEUTICS INC AS OF JANUARY 31, 2018 - SEC FILING Source text - (http://bit.ly/2nZykxi) Further company coverage:

BRIEF-Audentes Therapeutics Says Public Offering Of 5.75 Mln Shares Priced At $35/Share

* AUDENTES THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Therapeutics To Offer $150 Million Of Common Stock In Public Offering​

* AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

BRIEF-Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy

BRIEF-Audentes Therapeutics files for mixed shelf offering of up to $250 mln

* Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing Source text: (http://bit.ly/2fqe6ME) Further company coverage:

BRIEF-Audentes Therapeutics appoints Fulvio Mavilio to vice president scientific affairs, Europe

* Audentes Therapeutics announces appointment of Fulvio Mavilio, Ph.D. To vice president scientific affairs, Europe Source text for Eikon: Further company coverage:

BRIEF-Audentes Therapeutics qtrly loss per share $0.83

* Audentes therapeutics reports first quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics files for common stock offering of about 4.8 mln shares

* Files for common stock offering of about 4.8 million shares - sec filing Source text: (http://bit.ly/2puDjWw) Further company coverage:

BRIEF-Audentes Therapeutics announces proposed public offering of common stock

* Audentes Therapeutics announces proposed public offering of common stock

BRIEF-Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy

* Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up